Pulmonary Arterial Hypertension Associated With Portal Hypertension

(S)-8-{2-Amino-6-[1-(5-chloro-biphenyl-2-yl)-(R)-2,2,2-trifluoro-ethoxy]-pyrimidin-4-yl}-2,8-diaza-spiro[4.5]decane-3-carboxylic acid ethyl ester, 2-{[(1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexy]methoxy} acetic acid, Beraprost sodium ( DORNER ), Elafin, Iloprost ( VENTAVIS ), Imatinib mesilate ( GLEEVEC, GLIVEC, IMATINIB TEVA, IMATINIB TEVA B.V. ), Lisuride hydrogen maleate, Macitentan ( OPSUMIT ), Methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]-5-pyrimidinyl(methyl)carbamate, N-(tert-butylcarbamoyl)-5-cyano-2-((4'-(difluoromethoxy)-[1,1'-biphenyl]-3-yl)oxy)benzenesulfonamide, Platelet-derived growth factor (PDGF) receptor kinase inhibitor, Ralinepag, Riociguat ( ADEMPAS ), Sodium nitrite, Tacrolimus ( ENVARSUS XR, PROGRAF ), Treprostinil sodium (inhalation use) ( TYVASO, REMODULIN ), Ubenimex, Vasoactive intestinal peptide (VIP)-elastin-like peptide (ELP) fusion protein